Early access
Sign in
Taking people in ItalyPhase 1

Tests CLN-978 in adults with rheumatoid arthritis that treatments have not controlled

Tests CLN-978 in adults with rheumatoid arthritis that has not responded to prior treatment.

Key facts

Who runs it
Cullinan Therapeutics Inc.
Where
Rome and Rozzano, ItalySee the 2 sitesAlso in 2 other countries, 7 sites
Registry title
A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)
Status
Recruiting
Phase
Phase 1
People taking part
85 people, planned
Started
15 May 2025
Expected to end
1 Nov 2030
Type of study
Interventional
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with rheumatoid arthritis that has not responded to treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Rheumatoid arthritis that has not responded to treatment (treatment-refractory).

Where in Italy

Also in 2 other countries, 7 sites

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
  • Humanitas Mirasole S.p.A.Rozzano, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests CLN-978 in adults with rheumatoid arthritis that treatments have not controlledGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026